JoyL is the General Manager of Pfizer CentreOne, a global contract development and manufacturing organization (CDMO) and a leading supplier of specialty APIs embedded within Pfizer. In 2019, under her leadership, Pfizer CentreOne contributed $810M in revenue with a growth rate of 9% while advancing Pfizer’s purpose of delivering breakthroughs that change patients’ lives. In 2020 Pfizer CentreOne received the Life Science Leader and Outsourced Pharma CMO Leadership Award for the fourth consecutiv...
Jul 29, 2020•21 min
Abbas Kazimi is the Vice President, Head of Business Development at Nimbus Therapeutics, a biotechnology company harnessing quantum mechanics and computational approaches to structural biology to design breakthroughs in medicine. Abbas joined Nimbus in 2014 as Director of Business Development and has driven several of the company’s key transactions that have brought over $775M into Nimbus through financings and transactions, including the exclusive licensing agreement with Genentech, the sale of...
Jul 22, 2020•32 min
Dr. Randy Schatzman, Ph.D., is the chief executive officer and a board member of Bolt Biotherapeutics since 2019. He has over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registr...
Jul 15, 2020•20 min
Dr. Glenn Rosen has spent the bulk of his career engaged in basic and translational research in cancer and fibrosis. From 1993-2014, Dr. Rosen held a tenured faculty position in the Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University. He led a basic and translational research laboratory-his research focused on the study of dysregulated signaling in fibrosis and mechanisms of apoptosis resistance in solid tumors. He also led the clinical Interstitial Lung...
Jul 09, 2020•33 min
Diego is currently the Head of Research & Development of Global Rare Diseases at the Chiesi Group. Before this role, he was leading Chiesi’s development projects in rare diseases and advanced therapies and has more than 10 years experience in drug development, spanning from pre-clinical to commercial phase. Diego is an MD with a specialization in Internal Medicine. He obtained a PhD at the University of Parma (Italy) in cardiovascular pathophysiology and a post-doctoral fellowship in cardiov...
Jul 01, 2020•23 min
Dr. Clayman is a co-founder of Flexion Therapeutics and has served as our President, Chief Executive Officer and as one of our directors since our inception in 2007. Dr. Clayman also serves as the Chairman of the board of directors of both Anokion SA and Ribometrix. Previously, Dr. Clayman had a lengthy career at Eli Lilly and Company, where he was most recently Vice President, Lilly Research Laboratories, and General Manager of Chorus, Lilly’s early-phase development accelerator. During his car...
Jun 24, 2020•25 min
Dr. Colón brings over 25 years of experience in biopharma, genomics, healthcare and industrial biotechnology. In addition to her role at InCarda, she is Executive Chairman (formerly CEO) of ProterixBio, and serves on the boards of CareDx (NASDAQ:CDNA) and Cocoon Biotech and on the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University. Formerly, she was a partner at New Science Ventures, a New York based venture capital firm with over $700M under management, an...
Jun 17, 2020•23 min
Recorded in January 2020, we spoke with Sachin Chandran, who is currently Executive Director and Head of Pharmaceutical Sciences at Catabasis Pharmaceuticals, Inc. in Boston. Sachin’s responsibilities include oversight of CMC, Tech-Ops and supply chain along with matrixed interactions with regulatory, quality, biology, clinical and commercial. Working in a lean organization and a virtual environment, Sachin brings a strategic mindset while operationalizing with a can-do attitude with the goal to...
Jun 10, 2020•23 min
Mike Novotny is the founder and CEO of Medrio. Mr. Novotny applies 20 years of experience in research and software to his eClinical SaaS vision. Prior to founding Medrio, Mr. Novotny was president of Ninaza, an EDC software company, and had previously held roles as a research associate at the U.N. and a manager of the fraud database at VISA. He holds a BA from Stanford University and an MBA from Columbia University. Mr. Novotny founded Medrio in 2005 in San Francisco.
Jun 03, 2020•35 min
David Mace is the Co-founder & CEO of SwiftScale Biologics, a life sciences startup based in San Francisco, California. SwiftScale Biologics accelerates time to market for protein drugs by turning a labor-intensive drug production scale-up challenge into a computational challenge. Previously David was an Entrepreneur in Residence at 8VC, where he focused on the intersection of biology & computer science. He is a graduate of the California Institute of Technology.
May 27, 2020•29 min
David Bates is a scientist, inventor, investor, and entrepreneur. He has co-founded several companies including Linus Health and Bode. He is a founding partner of Tamarisc Ventures and serves on the board of several high-growth technology companies. He is on the board of directors of TMCity Foundation and is Strategic Advisor to the Digital Medicine Society. He previously worked at Morningside Ventures where he focused on biotech, healthcare, and cleantech investments. David was also the Chief S...
May 20, 2020•35 min
Stephan is a co-Founder and Chief Scientific Officer at Anokion, bringing more than 15 years of research expertise in the fields of immunology, protein engineering, and platform technologies to the company. He earned his B.Sc. in Chemical Engineering from the University of Texas at Austin and a Ph.D. in Bioengineering from the Swiss Federal Institute of Technology (EPFL) in Lausanne. During his thesis work, Stephan co-invented and developed the immune tolerance technology platform that inspired ...
May 13, 2020•32 min
Robert J. Gould joined Fulcrum as president and CEO at the time of the company’s launch in 2016, bringing over 30 years of experience to the role. Previously, he served as president and CEO of Epizyme from 2010 to 2015. Prior to joining Epizyme, Robert served as director of novel therapeutics at Broad Institute of MIT and Harvard from 2006 to 2010. Robert spent 23 years at Merck where he held a variety of leadership positions, culminating in the role of vice president, licensing and external res...
May 04, 2020•33 min
Dr. Paul K. Wotton is the Chief Executive Officer at Obsidian Therapeutics. Obsidian is a biotechnology company pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE™ technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression. The cytoDRiVE™ platform can be applied to design controllable in...
Apr 27, 2020•30 min
Chris is Sr. Vice President, Technical Operations at Blueprint Medicines. He has over 25 years of commercial and clinical manufacturing experience in the biopharmaceutical industry and has been fortunate to help develop and commercialize numerous oncology medicines. He has been in his current role since October 2017.
Feb 26, 2020•32 min
Carl P. Decicco is a biopharmaceutical veteran with over 30+ years of experience in the industry. Over the course of his career, Carl has played a central role in the advancement of more than 200 compounds into clinical trials and the approval of more than 20 drugs across multiple therapeutic areas. He’s authored/Co-Authored more than 100 scientific papers in peer reviewed journals and is listed as an inventor on 26 patents.
Jan 23, 2020•27 min
Dr. Florian Wegener is the co-founder and CEO of ZAGENO, an award-winning online marketplace serving the needs of research scientists. He is also a board-certified physician.
Jan 07, 2020•34 min
Raman is the founder and global president of ramarketing - an international design, digital and PR agency that's in the business of helping ambitious contract service companies operating in the global biotech and pharmaceutical outsourcing sector get noticed.
Dec 17, 2019•26 min
In this episode, guest Kevin Bittorf, founder of the Advancing Drug Development Forum and Don Dickerson sat down with host Alok Tayi to discuss trends in modern manufacturing and pharmaceutical environments. Kevin Bittorf is an accomplished Senior Executive and Consultant with demonstrated success and a proven track record in pharmaceutical development, technical Innovation, and IoT.
Dec 10, 2019•23 min
Jon Hennek co-leads the Systems Innovation Team at Indigo Ag. He co-founded the team—whose mission is to create a vision for what agriculture could look like in the distant future and develop a strategy for the Indigo model to dramatically accelerate its adoption—in 2017 while at Flagship Pioneering.
Dec 03, 2019•31 min
Sven Karlsson is the co-founder, chief operating officer and chief business officer of Platelet BioGenesis. In this episode of Biotech2050, Sven talks about his background, how he came to founding Platelet BioGenesis and the problems he and his team are trying to solve with the world's only method of producing clinical-grade human platelets from induced pluripotent stem cells.
Nov 05, 2019•27 min
Dr. Jo Viney is an entrepreneurial scientist and experienced biotech executive. A self-described “drug-hunter”, she has successfully advanced a number of programs into the clinic. She is Co-Founder, President and CSO of Pandion Therapeutics, a startup company in Cambridge, MA focused on developing new therapies for treating autoimmune and inflammatory diseases. On this episode of Biotech2050, Jo talked about her journey to the biotech industry and how she came to founding Pandion Therapeutics, s...
Oct 29, 2019•27 min
John Keilty is the Chief Data Sciences Officer at Decibel Therapeutics and a Strategic advisor at Third Rock Ventures. He is a biologist and bioinformatics guy by training and has been active in the biotech space for over two decades. In his career, John has been responsible for building out genomix, and genetics capabilities for early stage biotech companies. In this episode of Biotech 2050, John goes through his journey into the biotech industry and the work he’s doing at Decibel Therapeutics ...
Oct 23, 2019•28 min
In this inaugural episode of Biotech2050, hosts Alok Tayi and Rahul Chatuverdi sits down with Lee Cooper, a seasoned biotech entrepreneur, lawyer, patient advocate, founder of Enlight Bio and the nonprofit Institute for Genetic Disease Prevention to talk about the importance of patient centricity in today’s modern biotech. Cooper writes and speaks on health innovation and bioethics. He has a JD and MBA from Columbia University, and a BA in Religion and Public Policy from Dartmouth College. Today...
Oct 15, 2019•38 min
This episode is a trailer launching our highly anticipated podcast, Biotech 2050. A think tank chronicling the disruptions changing the biotech industry over the next 50 years.
Oct 01, 2019•1 min
